A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Clinical trial NCT04680052 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04680052
- Sponsor
- Incyte Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-15
- Primary completion
- 2024-02-23
- Enrollment
- 654
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.